Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 1,019 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bipolar Clear all
Completed Phase 4 Interventional Results available

Tranylcypromine Treatment of Bipolar Depression

NCT01430455
View directory record Official record
Conditions
Bipolar Disorder I or II
Interventions
Tranylcypromine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2018 · Synced Oct 29, 2026, 11:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Menstrual Effects On Mood Symptoms in Bipolar Disorder

NCT00472615
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2009 · Synced Oct 29, 2026, 11:24 PM EDT
Completed Not applicable Interventional Results available

Insulin Resistance in Patients With Mood Disorder

NCT00242619
View directory record Official record
Conditions
Depression, Bipolar Disorder, Insulin Resistance
Interventions
rosiglitazone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Oct 29, 2026, 11:24 PM EDT
Terminated Not applicable Interventional Results available

Music Therapy Advocacy Recording Intervention (MTAR) on Internalized Stigma

NCT05723328
View directory record Official record
Conditions
Mental Health Issues, Bipolar Disorder, Depressive, Schizophrenia Spectrum and Other Psychotic Disorders, Anxiety Disorder
Interventions
Group Music Therapy Advocacy Recording Intervention (MTAR)
Behavioral
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Belle Mead, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 29, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression

NCT02600507
View directory record Official record
Conditions
Bipolar Depression
Interventions
Lumateperone (ITI-007), Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
42
States / cities
Rogers, Arkansas • Cerritos, California • Costa Mesa, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 29, 2026, 11:24 PM EDT
Completed Not applicable Interventional Results available

Varenicline in Bipolar Depressed Patients

NCT00813800
View directory record Official record
Conditions
Smoking, Bipolar Disorder, Depression
Interventions
Varenicline
Drug
Lead sponsor
Mark Frye
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 30, 2012 · Synced Oct 29, 2026, 11:24 PM EDT
Completed Not applicable Interventional

Mindfulness Based Cognitive Therapy for Youth With Anxiety at Risk for Bipolar Disorder

NCT02090595
View directory record Official record
Conditions
Anxiety, Bipolar Disorder
Interventions
MBCT-C, Waitlist Control
Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
10 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 29, 2026, 11:24 PM EDT
Completed Phase 1 Interventional

Effectiveness of Lithium and Valproate in Treating High-Risk Bipolar Disorder

NCT00563992
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium, Valproic acid
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2012 · Synced Oct 29, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder

NCT00490971
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Olanzapine, Paliperidone ER, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
16
States / cities
Scottsdale, Arizona • Riverside, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 29, 2026, 11:24 PM EDT
Completed Phase 2 Interventional Results available

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

NCT01731119
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS, Autistic Disorder, Asperger Syndrome, Child Development Disorders, Pervasive, Bipolar I Disorder, Bipolar II Disorder, Mood Disorder NOS, Severe Major Depression With Psychotic Features, Single Episode Major Depression Without Psychotic Symptoms, Severe Mood Disorder With Psychotic Features
Interventions
Latuda©
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Years to 19 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 29, 2026, 11:24 PM EDT
Completed Not applicable Interventional Results available

Real-Time Mobile Cognitive Behavioral Intervention for Serious Mental Illness

NCT02035202
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
CBT2go, Smartphone
Behavioral · Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 29, 2026, 11:24 PM EDT
Completed Phase 4 Interventional Results available

Study Comparing Outcomes for Patients With Treatment Resistant Depression Who Receive VNS Therapy at Different Doses

NCT00305565
View directory record Official record
Conditions
Depression
Interventions
VNS Therapy
Device
Lead sponsor
Cyberonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
26
States / cities
Tucson, Arizona • Sacramento, California • Marietta, Georgia + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Oct 29, 2026, 11:24 PM EDT
Completed Phase 3 Interventional

Study of Quetiapine Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomanic Symptoms or Mild Manic Symptoms

NCT00277667
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Quetiapine
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 13, 2009 · Synced Oct 29, 2026, 11:24 PM EDT
Recruiting No phase listed Observational

University of Iowa Interventional Psychiatry Service Patient Registry

NCT04480918
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Episode, Major Depression, Major Depressive Disorder, Bipolar Disorder, Bipolar Depression, Obsessive-Compulsive Disorder
Interventions
Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Ketamine, Esketamine, Deep Transcranial Magnetic Stimulation (dTMS)
Device · Drug
Lead sponsor
Mark Niciu
Other
Eligibility
18 Years to 99 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2050
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 29, 2026, 11:24 PM EDT
Completed Phase 3 Interventional

Depression And Bipolar Disorder

NCT00274677
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Placebo, lamotrigine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
19
States / cities
Burbank, California • Loma Linda, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 29, 2026, 11:24 PM EDT
Completed Not applicable Interventional

Early Assessment and Intervention for Adolescents at Risk for Bipolar Disorder

NCT03203707
View directory record Official record
Conditions
Bipolar Disorder, Early Intervention
Interventions
Interpersonal and Social Rhythm Therapy
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 29, 2026, 11:24 PM EDT
Completed Phase 1 Interventional

Mindfulness-Based Cognitive Therapy for Perinatal Women With Mood Disorders

NCT02150681
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Disorder
Interventions
Mindfulness-based cognitive therapy
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Los Angeles, California • Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated May 30, 2014 · Synced Oct 29, 2026, 11:24 PM EDT
Completed Phase 3 Interventional

Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)

NCT01395992
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
asenapine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 29, 2026, 11:24 PM EDT
Active, not recruiting Phase 2 Interventional

Psilocybin Therapy for Depression in Bipolar II Disorder

NCT05065294
View directory record Official record
Conditions
Bipolar II Disorder
Interventions
Psilocybin therapy
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 29, 2026, 11:24 PM EDT
Completed Phase 4 Interventional

Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder

NCT00139594
View directory record Official record
Conditions
Bipolar Disorder
Interventions
licarbazepine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
13
States / cities
La Palma, California • Kansas City, Kansas • Shreveport, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 29, 2026, 11:24 PM EDT
Not listed Not applicable Interventional

Micronutrients as Adjunctive Treatment for Bipolar Disorder

NCT03541031
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Micronutrient & Fish oil, Olive oil & Safflower oil
Dietary Supplement
Lead sponsor
Eastern Maine Medical Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bangor, Maine
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Oct 29, 2026, 11:24 PM EDT
Terminated Phase 4 Interventional

Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness

NCT00071253
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Divalproex Sodium (Delayed-Release Tablets), Divalproex Sodium (Extended-Release Tablets), Olanzapine
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
15
States / cities
Anaheim, California • Chula Vista, California • Fort Meyers, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2006 · Synced Oct 29, 2026, 11:24 PM EDT
Recruiting Not applicable Interventional

Suicidal Behavior in Patients Diagnosed With Bipolar Disorder

NCT02604277
View directory record Official record
Conditions
Depression, Alcoholism, Drug Abuse
Interventions
Interpersonal and Social Rhythm Therapy (ISRT), Bipolar-Specific Cognitive Behavioral Therapy (CBT), Mindfulness-Based Stress Reduction (MBSR), Psycho-education & Understanding Bipolar Medications Therapy
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 64 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 29, 2026, 11:24 PM EDT
Completed Phase 4 Interventional

Study of Depakote ER for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder

NCT00181727
View directory record Official record
Conditions
Bipolar Disorder, Mania
Interventions
divalproex sodium extended release
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Oct 29, 2026, 11:24 PM EDT